



D. C.
29/01
Patent
231/003

RECE

AUG 12

TECH CENTER
21/Election

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1644
Thomas Kipps, et al.) Examiner: P. Gambel
Serial No.: 08/982,272)
Filed: December 1, 1997)
For: NOVEL EXPRESSION VECTORS)
CONTAINING ACCESSORY MOLECULE)
LIGAND GENES AND THEIR USE FOR)
IMMUNOMODULATION AND)
TREATMENT OF MALIGNANCIES AND)
AUTOIMMUNE DISEASE)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the Office Action Summary mailed June 8, 2000, Applicants submit the following response:

The Examiner required the election of a single disclosed species, stating that "these species are distinct because their structures, interactions, modes of action are different." Applicants wish to elect species A) CD40 ligand alone as the accessory molecule ligand. Applicants understand that should a generic claim be held allowable, Applicants will be entitled to consideration of claims to

SD-152773.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

7/31/00
Date of Deposit

Diana Neuner
Name of Person Mailing Paper

Diana Neuner
Signature of Person Mailing Paper



RECEIVED

Aug 11 2000

Patent
231/003

additional species that are written in dependent form or otherwise include all the limitations of an allowed generic claim, as provided by 37 CFR 1.141.

A petition for a one month extension of time is enclosed herewith. Should the Examiner find that a telephonic interview is in order, he is invited to telephone the undersigned.

Respectfully submitted,

LYON & LYON LLP

Dated: July 31, 2000

By: Sheryl Silver
Sheryl R. Silverstein
Reg. No. 40,812

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
Phone: (858) 552-8400
Fax: (213) 955-0440